Showing results (61-70 of 94) with videos related to
Sort By:
Pageof 10
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 4, 1993
Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effectsR M Bukowski, S Murthy, D McLain, et al.Cancer Research|August 15, 1991
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinomaR M Bukowski, W Sharfman, S Murthy, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1993
Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytesM J Thomassen, J M Antal, M J Connors, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group StudyG T Budd, T R Fleming, R M Bukowski, et al.Hepatology (Baltimore, Md.)|December 17, 2016
Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver diseaseFernando Bril, Diana Barb, Paola Portillo-Sanchez, et al.Cancer|December 18, 2001
Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of careB K Link, G T Budd, S Scott, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1995
Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup studyG T Budd, S Green, R M O'Bryan, et al.Plos One|November 7, 2015
Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer TumorigenesisWilliam T Budd, Sarah J Seashols-Williams, Gene C Clark, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effectsR M Bukowski, G T Budd, J A Gibbons, et al.Investigational New Drugs|August 25, 2000
Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomasT Chidiac, G T Budd, R Pelley, et al.Pageof 10